Gilead Sciences: Pharmaceutical Prices, Patents, And The FDAGuest Post
Gilead Sciences: Pharmaceutical Prices, Patents, And The FDA by Timothy D. Terrell, Mises Institute
In this article by economist Jeffrey Sachs, pharmaceutical company Gilead is taken to task for selling its hepatitis C cure, Sofosbuvir (sold as Sovaldi), at a price of $84,000 per course of treatment. Sachs says that the actual production cost of Sofosbuvir is about $100.
Sachs says that Gilead is "bilking the taxpayer" by charging the . . .
This content is exclusively for paying members. Sign up here
If you are subscribed and having an account error please clear cache and cookies if that does not work email firstname.lastname@example.org or click chat